Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.

AIMS: This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.

MATERIALS &

METHODS

A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.

RESULTS

402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; P < 0.01) and displayed significantly higher adherence to treatment.

CONCLUSIONS

In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.